Literature DB >> 27685538

Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.

Christoph Lange1,2,3,4,5, Raquel Duarte6, Mathilde Fréchet-Jachym7, Gunar Guenther1,2,3,5, Lorenzo Guglielmetti7,8, Ioana D Olaru1,2,3, Olena Oliveira6, Rudolf Rumetshofer9, Nicolas Veziris8,10, Frank van Leth11,12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27685538     DOI： 10.1164/rccm.201606-1097LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  12 in total

1.  The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?

Authors:  Cynthia B E Chee; Kyi-Win KhinMar; Li-H Sng; Roland Jureen; Jeffery Cutter; Vernon J M Lee; Yee-Tang Wang
Journal:  Eur Respir J       Date:  2017-08-10       Impact factor: 16.671

2.  Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.

Authors:  Clarisse A Tsang; Neha Shah; Lori R Armstrong; Suzanne M Marks
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

3.  Implementation of multidrug-resistant tuberculosis (MDR-TB) treatment in Gabon: lessons learnt from the field.

Authors:  U Ateba-Ngoa; J R Edoa; B R Adegbite; E G Rossatanga; D Madiou; A Mfoumbi; C Mevyann; P Achimi Agbo; J Mahoumbou; S Gould; B Lell; A A Adegnika; C Köhler; P G Kremsner; M Massinga-Loembe; A Alabi; M P Grobusch
Journal:  Infection       Date:  2019-05-09       Impact factor: 3.553

4.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

Review 5.  The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis.

Authors:  Graham Bothamley
Journal:  Breathe (Sheff)       Date:  2017-09

6.  Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis.

Authors:  Juliane Havlicek; Beatrice Dachsel; Peter Slickers; Sönke Andres; Patrick Beckert; Silke Feuerriegel; Stefan Niemann; Matthias Merker; Ines Labugger
Journal:  Diagn Microbiol Infect Dis       Date:  2018-12-30       Impact factor: 2.803

7.  Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic.

Authors:  Zarir F Udwadia; Jeffrey A Tornheim; Shashank Ganatra; Andrea DeLuca; Camilla S Rodrigues; Amita Gupta
Journal:  BMC Infect Dis       Date:  2019-01-28       Impact factor: 3.090

8.  Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan.

Authors:  Shona Horter; Jay Achar; Nell Gray; Nargiza Parpieva; Zinaida Tigay; Jatinder Singh; Beverley Stringer
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

Review 9.  WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea.

Authors:  Doosoo Jeon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-09-01

10.  Multidrug- and Extensively Drug-Resistant Mycobacterium tuberculosis Beijing Clades, Ukraine, 2015.

Authors:  Matthias Merker; Elena Nikolaevskaya; Thomas A Kohl; Barbara Molina-Moya; Olha Pavlovska; Patrik Brännberg; Andrii Dudnyk; Valentyna Stokich; Ivan Barilar; Iryna Marynova; Tetiana Filipova; Cristina Prat; Anders Sjöstedt; Jose Dominguez; Olena Rzhepishevska; Stefan Niemann
Journal:  Emerg Infect Dis       Date:  2020-03       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.